Evidence map›Paper›PMID 34273116›Full record

ArticleJournal of medical virology2021

Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalized Covid-19 patients.

Charlotte Wenban, Randeep S Heer, Vadir Baktash, Pirabakaran Kandiah, Theodora Katsanouli, Asmita Pandey, Ryan Goindoo, Afiyah Ajaz, Koenraad Van den Abbeele, Amit K J Mandal and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Charlotte WenbanDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.ORCID http://orcid.org/0000-0002-4416-7393
Randeep S HeerDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.ORCID http://orcid.org/0000-0002-6094-6389
Vadir BaktashDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Pirabakaran KandiahDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Theodora KatsanouliDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Asmita PandeyDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Ryan GoindooDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Afiyah AjazDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Koenraad Van den AbbeeleDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Amit K J MandalDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.ORCID http://orcid.org/0000-0003-0986-5927
Constantinos G MissourisDepartment of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Wexham Park Hospital · GBUniversity of Nicosia · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe have previously demonstrated that vitamin D deficiency might be associated with worse outcomes in hospitalized Covid-19 patients. The aim of our study was to explore this relationship with dexamethasone therapy.

methodsWe prospectively studied two cohorts of hospitalized Covid-19 patients between March and April and between September and December 2020 (n = 192). Patients were tested for serum 25-hydroxyvitamin D (25-OH-D) levels during admission. The first cohort not treated with dexamethasone (n = 107) was divided into vitamin D deficient (25-OH-D ≤ 30 nmol/L) (n = 47) and replete subgroups (25-OH-D > 30 nmol/L) (n = 60). The second cohort treated with dexamethasone (n = 85) was similarly divided into deficient (25-OH-D ≤ 30 nmol/L) (n = 27) and replete subgroups (25-OH-D > 30 nmol/L) (n = 58). Primary outcome was in-hospital mortality and secondary outcomes were elevation in markers of cytokine storm and ventilatory requirement.

resultsNo mortality difference was identified between cohorts and subgroups. The "no dexamethasone" cohort 25-OH-D deplete subgroup recorded significantly higher peak D-Dimer levels (1874 vs. 1233 µgFEU/L) (p = 0.0309), CRP (177 vs. 107.5) (p = 0.0055), and ventilatory support requirement (25.5% vs. 6.67%) (p = 0.007) compared to the replete subgroup. Among the 25-OH-D deplete subgroup higher peak neutrophil counts, peak CRP, peak LDH, peak ferritin, and lower trough lymphocyte counts were observed, without statistical significance. In the "dexamethasone" cohort, there was no apparent association between 25-OH-D deficiency and markers of cytokine storm or ventilatory requirement.

conclusionVitamin D deficiency is associated with elevated markers of cytokine storm and higher ventilatory requirements in hospitalized Covid-19 patients. Dexamethasone treatment appears to mitigate adverse effects of vitamin D deficiency.

Indexed as

COVID-19 Drug TreatmentAgedAged, 80 and overCOVID-19Cytokine Release SyndromeCytokinesDexamethasoneFemaleHospitalizationHumansMaleProspective StudiesTreatment OutcomeVitamin DVitamin D Deficiency25-hydroxyvitamin DCytokinesDexamethasoneVitamin Dcovid-19cytokine stormdexamethasoneventilationvitamin D

Identifiers

PMID34273116
PMCPMC8426812
OpenAlexW3181876725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.